United States Patent 5,580,755: Claim Scope, Validity Risks, and the US Landscape for Serine-Substituted hpG-CSF
What does US 5,580,755 actually claim?
US Patent 5,580,755 is directed to a human pluripotent granulocyte colony-stimulating factor (hpG-CSF) polypeptide with a narrowly engineered cysteine-to-serine substitution pattern at specified positions, plus a basic formulation claim covering a carrier.
Claim 1 (core composition-of-matter)
Claim 1 covers:
- An isolated human pluripotent granulocyte colony stimulating factor (hpG-CSF) polypeptide, where the amino acid sequence is selected from the group consisting of (sequence list is not reproduced in the excerpt you provided), and
- Analogs thereof in which one or more cysteine residues located at positions 17, 36, 42, 64, and 74 are replaced by serine.
Scope mechanics
- The claim is an amino-acid substitution claim with a defined substitution set (cysteines at 5 named positions) and a defined replacement amino acid (serine).
- It covers both the enumerated baseline sequences (the “selected from the group consisting of …” portion) and analogs that fall within the substitution pattern.
Practical read
- A commercial or competitor molecule that changes any subset of cysteines among {17, 36, 42, 64, 74} → serine falls within claim 1, even if other differences exist, unless limited by other unquoted sequence-language requirements embedded in the omitted sequence list.
Claim 2 (formulation)
Claim 2 covers:
- A composition comprising the claim-1 hpG-CSF polypeptide and a carrier.
Scope mechanics
- This is a classic formulation-with-carrier claim. Without carrier limitations (buffer type, sterility, concentration, stabilizers), it covers a broad class of conventional carriers used for cytokine proteins (aqueous solutions, lyophilized powders reconstituted with standard excipients, etc.).
Where is the claim strongest and where it breaks down
Strength: defined substitution chemistry
The substitution rule is concrete:
- Positions: 17, 36, 42, 64, 74
- Replacement: cysteine → serine
This can strengthen novelty over prior art if prior art does not teach that precise cysteine set or does not teach that exact serine substitution to address stability, folding, aggregation, or receptor interactions.
Weakness: broad “one or more”
Claim 1 says “one or more cysteines residues … are replaced by serine.”
That means it covers:
- Single substitutions
- Multi-substitutions across that set
- Possibly even all five cysteines substituted
This broadens coverage but also increases anticipated obviousness pressure if prior art identifies general cysteine-to-serine engineering or general reduction of disulfide bonding for cytokine stabilization.
Weakness: “selected from the group consisting of …” ambiguity
Your excerpt omits the actual sequence(s) under “selected from the group consisting of.” The scope depends on those specific baseline sequences. Two risks follow:
- If the enumerated sequences are too short or too general, the claim may overlap widely with known G-CSF variants and antibody-validated analogs.
- If the sequences are narrow and tied to a specific hpG-CSF identity that prior art does not match, enforceability improves but infringement requires exact mapping to that sequence class.
How does this relate to the known G-CSF patent landscape?
Core competitive benchmark: filgrastim vs. engineered G-CSFs
In the US market, the dominant approved products are typically filgrastim (recombinant human G-CSF) and pegfilgrastim (PEGylated filgrastim). These are not defined by your claimed cysteine substitution pattern alone; they are defined by their particular sequence and processing.
Implication for landscape analysis
- The claim targets hpG-CSF and a specific engineered cysteine substitution scheme, which can be viewed as an attempt to carve out a variant class rather than the baseline recombinant protein.
- That approach often collides with older cytokine engineering disclosures, where substitution at cysteine positions is a standard tactic for stability or reduced aggregation.
Why cysteine positions matter
Cysteines in secreted cytokines usually relate to:
- Disulfide-bond structure
- Fold stability
- Glycoprotein processing (if applicable)
- Protein aggregation propensity
Replacing cysteines with serine is a classic move to avoid disulfide scrambling or to alter folding kinetics. That makes it an obvious knob unless the prior art lacks motivation to try exactly these positions and exactly serine replacements.
What would a validity attack target for US 5,580,755?
1) Anticipation (single-reference novelty defeat)
An anticipation attack would focus on a reference that discloses:
- hpG-CSF with the same amino-acid identity as the claimed sequences; and
- explicit cysteine-to-serine replacements at the claimed positions, or discloses a sequence that inherently includes that substitution pattern.
If the prior art includes:
- The baseline hpG-CSF sequence, and
- A variant with some or all of Cys17/Cys36/Cys42/Cys64/Cys74 → Ser, then claim 1 fails on novelty.
2) Obviousness (combination or motivation)
An obviousness attack typically uses:
- A prior art cytokine engineering disclosure showing cysteine substitution for stability; plus
- Motivation to apply that engineering to G-CSF analogs; and
- A reasonable expectation of success for serine substitution.
Because claim 1 is limited only by:
- a fixed set of five cysteine positions; and
- serine as the replacement,
it is easier for an examiner or challenger to argue that the substitution is an expected optimization within a known engineering playbook.
3) Claim indefiniteness or lack of support (depending on the omitted sequence list)
If the underlying patent specification defines specific numbered positions relative to a specific reference sequence, challengers often attack whether the claim properly supports:
- the exact numbering positions (17, 36, 42, 64, 74) across the claimed “selected from the group consisting of” sequences; and
- the “analogs thereof” boundary.
If the specification does not clearly anchor numbering to an unambiguous sequence, interpretive disputes arise.
4) “Carrier” formulation breadth
Claim 2 is broad and usually easier to invalidate if prior art already disclosed:
- the same protein (or an obvious variant within claim 1), formulated with typical carriers.
However, formulation claims are often more defensible when tied to specific stabilization systems. Claim 2 as presented is not.
What does an infringement analysis hinge on?
For claim 1
A literal infringement theory requires:
- The accused product contains an isolated hpG-CSF polypeptide.
- Its amino-acid sequence is within the claim’s defined set:
- either exactly one of the enumerated sequences in the omitted “selected from the group consisting of …” portion, or
- It is an “analog” with cysteine-to-serine substitution at one or more of the specified positions.
If the competitor changes different residues (e.g., cysteine to alanine, glycine, or changes other residues beyond the cysteine set), infringement depends on whether claim interpretation requires only the cysteine changes or also requires the rest of the sequence to match a particular disclosed baseline.
For claim 2
Infringement is more straightforward if the accused product is a known composition of that hpG-CSF variant with any conventional carrier.
Where does the patent sit in the broader US expiration and enforcement reality?
US patents filed in the era of early recombinant cytokine families often have:
- term ending roughly 20 years from effective filing (subject to adjustments),
- with potential earlier expiration depending on application priority dates and prosecution history.
Given US 5,580,755 issued in the late 1990s, it is likely to be long expired or near-expired for most current market entries. That affects practical enforceability more than claim scope alone.
Critical mapping: how the claim differentiates vs. prior art
Differentiators
- Specificity of the cysteine replacement set: 17, 36, 42, 64, 74 → Ser
- Engineering claim format: amino acid substitutions for a particular cytokine family (hpG-CSF)
Likely overlaps
- Prior art G-CSF engineering literature commonly explores:
- cysteine modifications to alter disulfide pattern,
- reduction of aggregation,
- expression and secretion stability optimization.
- Formulation with carriers is usually routine.
What the claim does not limit
- No explicit requirements on:
- disulfide bond pattern,
- glycosylation state,
- purity, aggregate level,
- stability metrics,
- administration route,
- dosing regimen,
- pegylation or fusion formats.
- Claim 2 has a generic carrier limitation.
Those omissions reduce differentiation against routine protein formulation prior art.
Business impact: how to treat this patent in R&D decisions
If you are designing new hpG-CSF variants
This patent is best treated as a substitution-pattern fence:
- Any candidate that implements cysteine-to-serine swaps at those positions risks overlapping claim 1.
- Candidates that preserve cysteines (or replace them with a non-serine residue) may reduce risk, but only if they also avoid matching the rest of the hpG-CSF sequence set and analog boundaries.
If you are doing formulation-only development
Claim 2 is a low-barrier coverage claim:
- If you already have a product within claim 1’s protein scope, formulation changes using conventional carriers are unlikely to escape.
If you are operating in parallel with known carrier formulations, the formulation claim adds little additional deterrence.
Key takeaways
- Claim 1 is a variant class defined by cysteine-to-serine substitutions at positions 17, 36, 42, 64, 74 in hpG-CSF polypeptides, covering baseline enumerated sequences and “analogs” with any subset of those substitutions.
- Claim 2 is a broad protein + carrier formulation claim with no limiting excipient, stability, purity, or presentation constraints.
- Validity pressure is structurally high for claim 1 because “one or more” substitutions across a known engineering knob (cysteine modification) fits common obviousness narratives unless prior art lacks the exact substitution mapping or lacks motivation to apply serine replacements at those precise positions.
- Infringement will turn on exact match to the hpG-CSF sequence set and presence of the claimed cysteine-to-serine pattern at the specified numbered positions.
- The practical enforceability is likely limited by the age of US 5,580,755 relative to typical 20-year term timelines for US patents issued in the late 1990s.
FAQs
1) Does the patent protect only fully substituted proteins (all five cysteines to serine)?
No. Claim 1 covers “one or more” cysteines among positions 17, 36, 42, 64, 74 replaced by serine.
2) Is the formulation claim limited to a specific excipient system?
No. Claim 2 covers a composition with the protein and a carrier without specifying composition constraints.
3) Would changing cysteines to a different amino acid avoid claim 1?
Potentially yes for the substitution element, since claim 1 requires serine as the replacement.
4) What is the most sensitive part of claim 1 for infringement analysis?
The accused protein must satisfy the hpG-CSF sequence identity/analog boundary and must include the cys-to-ser substitutions at the numbered positions.
5) What is the most likely patentability attack vector for claim 2?
If claim 1 is defeated (or the protein is already known), claim 2’s carrier limitation is usually too generic to preserve patentability over routine protein formulations.
References
[1] United States Patent 5,580,755.
